Shield Therapeutics secures EMA support to expand FeRACCRU use to adolescents

Shield Therapeutics (LSE:STX) has received a regulatory boost after a European Medicines Agency committee recommended extending the approved use of FeRACCRU to include adolescent patients. The positive opinion allows the iron deficiency treatment to be prescribed for individuals aged 12 and above, expanding its existing patient base.

The recommendation follows completion of the company’s agreed pediatric investigation plan and is supported by encouraging Phase 3 trial results demonstrating the efficacy and safety of ferric maltol in children. The development strengthens the drug’s pediatric profile in Europe, complementing earlier regulatory approval for similar use in the United States.

Under Shield’s European licensing agreement, Norgine holds the marketing authorisation for FeRACCRU and will be responsible for commercialising the expanded indication across the region. The regulatory milestone will trigger a €500,000 payment to Shield under the terms of the partnership.

The approval is expected to support broader adoption of ferric maltol and enhance its position in the global iron deficiency treatment market as a differentiated oral therapy. It also aligns with Shield’s strategy of leveraging regional commercial partners to expand revenues outside the United States.

From an investment perspective, the company’s outlook reflects a mix of encouraging corporate developments and financial headwinds. Recent regulatory progress and strong technical momentum in the share price offer positive signals. However, ongoing financial challenges and valuation concerns remain key risks for investors.

More about Shield Therapeutics

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on the treatment of iron deficiency and iron deficiency anaemia. Its ferric maltol product is marketed as ACCRUFeR in the United States and FeRACCRU in Europe and other international markets. The company operates through licensing partnerships with regional pharmaceutical firms, including Viatris in the U.S. and Norgine in Europe, alongside additional partners across Canada, Asia-Pacific and China. Patent protection for ferric maltol is expected to extend into the mid-2030s.